Breaking News

BriaCell Reports $4M Strategic Investment with Prevail Partners

Prevail to provide clinical services and technologies for BriaCell’s upcoming study in advanced metastatic breast cancer.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, signed a master service and technology agreement (MSTA) agreement with Prevail InfoWorks, Inc. (InfoWorks), a Philadelphia-based contract research organization (CRO), to provide clinical services and technologies for BriaCell’s upcoming pivotal study in advanced metastatic breast cancer. Services include clinical site coordination, project management, clinical monitoring, a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters